234 related articles for article (PubMed ID: 17294898)
1. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
[TBL] [Abstract][Full Text] [Related]
2. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
De Botton S; Chevret S; Sanz M; Dombret H; Thomas X; Guerci A; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Cony Makhoul P; Travade P; Solary E; Fegueux N; Bordessoule D; San Miguel J; Link H; Desablens B; Stamatoullas A; Deconinck E; Geiser K; Hess U; Maloisel F; Castaigne S; Preudhomme C; Chomienne C; Degos L; Fenaux P;
Br J Haematol; 2000 Dec; 111(3):801-6. PubMed ID: 11122141
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
4. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
Slack JL; Arthur DC; Lawrence D; Mrózek K; Mayer RJ; Davey FR; Tantravahi R; Pettenati MJ; Bigner S; Carroll AJ; Rao KW; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 May; 15(5):1786-95. PubMed ID: 9164186
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia. New methods in diagnosis and treatment.
Varghese L; Janckila A; Yam LT
J Ky Med Assoc; 1999 Feb; 97(2):61-5. PubMed ID: 10073058
[TBL] [Abstract][Full Text] [Related]
7. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
8. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.
Mandelli F; Diverio D; Avvisati G; Luciano A; Barbui T; Bernasconi C; Broccia G; Cerri R; Falda M; Fioritoni G; Leoni F; Liso V; Petti MC; Rodeghiero F; Saglio G; Vegna ML; Visani G; Jehn U; Willemze R; Muus P; Pelicci PG; Biondi A; Lo Coco F
Blood; 1997 Aug; 90(3):1014-21. PubMed ID: 9242531
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
10. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
12. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Hernández JM; Martín G; Gutiérrez NC; Cervera J; Ferro MT; Calasanz MJ; Martínez-Climent JA; Luño E; Tormo M; Rayón C; Díaz-Mediavilla J; González M; González-San Miguel JD; Pérez-Equiza K; Rivas C; Esteve J; Alvarez Mdel C; Odriozola J; Ribera JM; Sanz MA;
Haematologica; 2001 Aug; 86(8):807-13. PubMed ID: 11522536
[TBL] [Abstract][Full Text] [Related]
13. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
14. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study.
Laczika K; Mitterbauer G; Korninger L; Knöbl P; Schwarzinger I; Kapiotis S; Haas OA; Kyrle PA; Pont J; Oehler L
Leukemia; 1994 Jan; 8(1):1-5. PubMed ID: 8289472
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukaemia and the t(15;17) translocation.
Gillard EF; Solomon E
Semin Cancer Biol; 1993 Dec; 4(6):359-67. PubMed ID: 8142621
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
20. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
